Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy (AXAFA)
An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation
Sponsor: Atrial Fibrillation Network
Listed as NCT02227550, this PHASE4 trial focuses on Atrial Fibrillation and remains completed. Sponsored by Atrial Fibrillation Network, it has been updated 8 times since 2014, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Nov 2017 — Feb 2018 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
May 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — May 2017 [monthly]
Recruiting PHASE4
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Atrial Fibrillation Network
- Bristol-Myers Squibb
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .